Biomarkers for the detection of early stage ovarian cancer
AssigneesVermilllion, Inc., Board of Regents, The University of Texas System
InventorsEric T. Fung, Charlotte Clarke, Robert C. Bast, JR., Kevin R. Coombes
Life of this patent
Estimating the term…
Abstract
The present invention provides methods and compositions for detecting early stage ovarian cancer in a patient. Also, methods for evaluating the ovarian cancer state of a patient are described herein. These methods involve the detection, analysis, and classification of biomarkers in biological samples.
Claims27
A method of determining an ovarian cancer patient's ovarian cancer status comprising:
- (a) determining the concentration or expression levels or peak intensity values of a combination of biomarkers in a sample from the subject, wherein the biomarkers comprise:
- (i) apolipoprotein A1 (ApoA1), (ii) transthyretin (TTR), (iii) inter-alpha (globulin) inhibitor H4 (plasma Kallikrein-sensitive glycoprotein) (ITIH4), (iv) transferrin (TFR) and (v) CA125, or (i) apolipoprotein A1 (ApoA1), (ii) transthyretin (TTR), (iii) CTAPIII, and (iv) CA125;
- and
- (b) correlating the measurements with ovarian cancer status.
A method of determining if a patient has early stage ovarian cancer comprising:
- (a) determining the concentration/expression levels/peak intensity values of a panel seven biomarkers in a sample from the subject, wherein the biomarkers (approximate m/z location) are (i) apolipoprotein A1 (ApoA1), (ii) transthyretin (TTR), (iii) inter-alpha (globulin) inhibitor H4 (plasma Kallikrein-sensitive glycoprotein) (ITIH4), (iv) transferrin (TFR) and (v) CA125 or (i) apolipoprotein A1 (ApoA1), (ii) transthyretin (TTR), (iii) CTAPIII, and (iv) CA125;
- and
- (b) correlating the measurement with ovarian cancer status
The method of claim 8 further comprising:
- (d) determining the m/z values for the panel of biomarkers after subject management.
A method of qualifying ovarian cancer status in a subject comprising:
- (a) providing a subject sample of blood or a blood derivative;
- (b) fractionating proteins in the sample on an anion exchange resin and collecting fractions that contain (i) apolipoprotein A1 (ApoA1), (ii) transthyretin (TTR), (iii) inter-alpha (globulin) inhibitor H4 (plasma Kallikrein-sensitive glycoprotein) (ITIH4), (iv) transferrin (TFR) and (v) CA125 or (i) apolipoprotein A1 (ApoA1), (ii) transthyretin (TTR), (iii) CTAPIII, and (iv) CA125;
- and
- (c) capturing (i) apolipoprotein A1 (ApoA1), (ii) transthyretin (TTR), (iii) inter-alpha (globulin) inhibitor H4 (plasma Kallikrein-sensitive glycoprotein) (ITIH4), (iv) transferrin (TFR) and (v) CA125 or (i) apolipoprotein A1 (ApoA1), (ii) transthyretin (TTR), (iii) CTAPIII, and (iv) CA125 from the fractions on a surface of a substrate comprising capture reagents that bind the protein biomarkers.
A kit comprising:
- (a) a capture reagent that binds a panel of biomarkers comprising (i) apolipoprotein A1 (ApoA1), (ii) transthyretin (TTR), (iii) inter-alpha (globulin) inhibitor H4 (plasma Kallikrein-sensitive glycoprotein) (ITIH4), (iv) transferrin (TFR) and (v) CA125, and
- (b) a container comprising at the panel of biomarkers.
A kit comprising:
- (a) a capture reagent that binds a panel of biomarkers comprising (i) apolipoprotein A1 (ApoA1), (ii) transthyretin (TTR), (iii) CTAPIII, and (iv) CA125;
- and
- (b) a container comprising at the panel of biomarkers.
A system comprising:
- (a) a plurality of capture reagents each of which has bound to it a different biomarker comprising (i) apolipoprotein A1 (ApoA1), (ii) transthyretin (TTR), (iii) inter-alpha (globulin) inhibitor H4 (plasma Kallikrein-sensitive glycoprotein) (ITIH4), (iv) transferrin (TFR) and (v) CA125 or (i) apolipoprotein A1 (ApoA1), (ii) transthyretin (TTR), (iii) CTAPIII, and (iv) CA125.
Dependencies are inferred from the claim text.